Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Quantitative proteomics to study a small molecule targeting the loss of von Hippel-Lindau in renal cell carcinomas.

Bouhamdani N, Joy A, Barnett D, Cormier K, Léger D, Chute IC, Lamarre S, Ouellette R, Turcotte S.

Int J Cancer. 2017 Aug 15;141(4):778-790. doi: 10.1002/ijc.30774. Epub 2017 May 25.

2.

(1)H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism.

Cuperlovic-Culf M, Cormier K, Touaibia M, Reyjal J, Robichaud S, Belbraouet M, Turcotte S.

Int J Cancer. 2016 May 15;138(10):2439-49. doi: 10.1002/ijc.29947. Epub 2016 Jan 29.

3.

Canadian guideline on genetic screening for hereditary renal cell cancers.

Reaume MN, Graham GE, Tomiak E, Kamel-Reid S, Jewett MA, Bjarnason GA, Blais N, Care M, Drachenberg D, Gedye C, Grant R, Heng DY, Kapoor A, Kollmannsberger C, Lattouf JB, Maher ER, Pause A, Ruether D, Soulieres D, Tanguay S, Turcotte S, Violette PD, Wood L, Basiuk J, Pautler SE; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2013 Sep-Oct;7(9-10):319-23. doi: 10.5489/cuaj.1496.

4.

Autophagy and cell death to target cancer cells: exploiting synthetic lethality as cancer therapies.

Reyjal J, Cormier K, Turcotte S.

Adv Exp Med Biol. 2014;772:167-88. doi: 10.1007/978-1-4614-5915-6_8. Review.

PMID:
24272359
5.

Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality.

Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, Reynolds GE, Chi JT, Wu J, Solow-Cordero DE, Bonnet M, Flanagan JU, Bouley DM, Graves EE, Denny WA, Hay MP, Giaccia AJ.

Sci Transl Med. 2011 Aug 3;3(94):94ra70. doi: 10.1126/scitranslmed.3002394.

6.

Targeting cancer cells through autophagy for anticancer therapy.

Turcotte S, Giaccia AJ.

Curr Opin Cell Biol. 2010 Apr;22(2):246-51. doi: 10.1016/j.ceb.2009.12.007. Epub 2010 Jan 6. Review.

7.

4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death.

Hay MP, Turcotte S, Flanagan JU, Bonnet M, Chan DA, Sutphin PD, Nguyen P, Giaccia AJ, Denny WA.

J Med Chem. 2010 Jan 28;53(2):787-97. doi: 10.1021/jm901457w.

8.
9.

A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.

Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA, Giaccia AJ.

Cancer Cell. 2008 Jul 8;14(1):90-102. doi: 10.1016/j.ccr.2008.06.004.

10.

Regulation of brain endothelial cells migration and angiogenesis by P-glycoprotein/caveolin-1 interaction.

Barakat S, Turcotte S, Demeule M, Lachambre MP, Régina A, Baggetto LG, Béliveau R.

Biochem Biophys Res Commun. 2008 Aug 1;372(3):440-6. doi: 10.1016/j.bbrc.2008.05.012. Epub 2008 May 15.

PMID:
18485890
11.

HIF gene expression in cancer therapy.

Chan DA, Krieg AJ, Turcotte S, Giaccia AJ.

Methods Enzymol. 2007;435:323-45. Review.

PMID:
17998061
12.

Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells.

Sutphin PD, Chan DA, Li JM, Turcotte S, Krieg AJ, Giaccia AJ.

Cancer Res. 2007 Jun 15;67(12):5896-905.

13.

Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.

Desrosiers RR, Cusson MH, Turcotte S, Béliveau R.

Int J Cancer. 2005 May 1;114(5):702-12.

14.

Diallyl disulfide, a chemopreventive agent in garlic, induces multidrug resistance-associated protein 2 expression.

Demeule M, Brossard M, Turcotte S, Regina A, Jodoin J, Béliveau R.

Biochem Biophys Res Commun. 2004 Nov 12;324(2):937-45.

PMID:
15474518
15.

von Hippel-Lindau tumor suppressor protein stimulation by thrombin involves RhoA activation.

Turcotte S, Desrosiers RR, Brand G, Béliveau R.

Int J Cancer. 2004 Dec 10;112(5):777-86.

16.

Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.

Turcotte S, Desrosiers RR, Beliveau R.

Am J Physiol Renal Physiol. 2004 Feb;286(2):F338-48. Epub 2003 Oct 28.

17.

Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation.

Annabi B, Lee YT, Turcotte S, Naud E, Desrosiers RR, Champagne M, Eliopoulos N, Galipeau J, Béliveau R.

Stem Cells. 2003;21(3):337-47.

18.

HIF-1alpha mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma.

Turcotte S, Desrosiers RR, Béliveau R.

J Cell Sci. 2003 Jun 1;116(Pt 11):2247-60. Epub 2003 Apr 15.

Supplemental Content

Loading ...
Support Center